INTRODUCTION

50
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long 51 disease for which no vaccines are yet available. With ~6 million people already infected 52 and up to 70 million individuals at risk of infection, Chagas disease constitutes one of the 53 most important parasitic disease in Latin America; and an emerging threat to global public 54 health (1, 2). T. cruzi transmission occurs when humans are exposed to the contaminated 55 feces of blood-sucking triatomine vectors, through the ingestion of tainted food/beverages 56 (3), via blood transfusion or organ transplantation (1) or congenitally (4, 5) . According to 57 epidemiological data, maternal-fetal transmission occurs in ~5% of T. cruzi-infected 58 mothers, which leads to ~15,000 new congenital cases per year (5).
59
Only two trypanocidal drugs, benznidazole (BZ) and nifurtimox (NX) are currently 60 available for chemotherapy. Both are oral compounds that may display adverse effects 61 (i.e. allergic dermatitis) and that cannot be used to treat pregnant women due to their 
65
However, a significant proportion of patients are negative for parasitological techniques 66 prior to treatment, thus making a subsequent negative result uninformative. PCR-based 67 methods were proven useful in certain clinical situations usually associated to patent blood 68 parasitemia such as congenital infections or disease reactivation in immunosuppressed 69 patients (7-10). However, they remain to be clinically validated and are not yet available in 70 regular health care centers. Moreover, some apparent false positive results due to trans-71 placental transfer of maternal parasite DNA have been described (7).
72
Conventional serological techniques such as enzyme-linked immunosorbent assay 
86
In previous works, we characterized a surface adhesion molecule from T. cruzi 87 bloodstream trypomastigotes termed TSSA (Trypomastigote Small Surface Antigen) (31-88 33). TSSA elicits a strong humoral response during human infections (31, (34) (35) (36) , and has 89 been validated for Chagas disease serodiagnosis (37). At variance with F2/3, most of anti-
90
TSSA antibodies are directed to peptide epitopes (33, 36, 38) , thus enabling the 91 straightforward production of a highly pure diagnostic reagent in engineered bacteria. 
149
A linear regression model was used to examine the course of antibody levels over time.
150
Because tELISA and TSSA-ELISA OD values were highly variable among different 151 patients, even among those from the same group, they were expressed as a percentage of 152 the OD value of the first specimen: pre-treatment sample (for patients from Groups 1 and 
162
Diego, CA, USA). CI were calculated using SPSS R Statistics (IBM R Versión20).
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( Table S5) 
210
Patients from Group 2 displayed significant differences (p=.01) in the serological 211 regression slopes assessed by TSSA-ELISA or tELISA (Fig. 2D ).
212
A total of 22 T. cruzi-infected patients (10/26 from Group 1 and 12/12 from Group 
214
and 10 from Group 2) were TSSA-reactive (Table S5 ). Interestingly, these 18 patients 215 seronegativized either before (n=16) or at the same time (n=2) for TSSA-ELISA than for 216 tELISA. Moreover, 3 patients from Group 1 achieved seronegativization in TSSA-ELISA
217
but not in tELISA (denoted as censored cases in Fig. 3A ). Kaplan-Meier curves comparing 218 the performance of both methods among seronegativized patients are plotted in Fig. 3 (Fig. 3B) .
224
Comparative analysis of tELISA data indicated that serological regression followed 225 distinct kinetics, being significantly faster (p<.0001) in Group 2 (slope: -10.53) than in
226
Group 1 (slope: -1.527) (Fig. 2 ). This in turn translated into significantly shorter (p<.0001)
227
time-periods to reach tELISA negativity threshold (median values: 5.4 and 32 months for
228
Groups 2 and 1, respectively) (Fig. 3) . In the same line, TSSA-ELISA revealed differences 
241
ELISA (n=36, since 3 patients were born to TSSA-non-reactive mothers (Table S5) ) and 242 tELISA (n=39) results are shown in Table S3 and Fig. S1 ; and linear regression analyses 243 upon these data are plotted in Fig. 4 . Both kinds of maternally-transferred antibodies
244
showed a steady declining early after birth, although with significant differences in their 245 regression slopes (Fig. 4A) 
263
values that are well within the range of non-infected children included in Group 3 (Fig. 4) .
264
Unexpectedly, REC52 yielded positive results for TSSA-ELISA at 10.5 months of age ( 
282
were significantly lower than those recorded for F2/3 (4 and 21.9 months, respectively) 283 (44). As mentioned, F2/3 is so far considered the best alternative serological marker for 284 treatment evaluation in Chagas disease (16, 28, 29) .
285
In addition of providing a novel tool able to shorten follow-up periods following 
295
One issue that needs to be addressed in order to improve the clinical value of
296
TSSA is that of its sub-optimal sensitivity, which may be attributed to variations in the antigenicity (31, 37, 46). In our study, for instance, TSSA prevalence was 86%, which is 301 consistent with previous data (~86-91%, (36, 37)). In the case of the two TSSA non-302 reactive children from Group 2, however, it is most notably that they were born to TSSA 303 reactive mothers (Table S2 ). It may be therefore hypothesized that both of them 
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